Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00974376 · ClinicalTrials.gov registry record · Phase 2
Gabapentin Treatment of Cannabis Dependence
A Phase 2 study, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00974376 is a Phase 2 study that has completed, run by The Scripps Research Institute. The registered enrollment target is 150 participants.
The verdict
NCT00974376, a Phase 2 study, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a clinical study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.
Interventions
- DRUG Placebo
- BEHAVIORAL Manual-guided behavioral counseling
- DRUG gabapentin 1200mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2009-11-04 |
| Est. Completion | 2016-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00974376
The ClinicalTrials.gov registry entry for NCT00974376 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00974376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00974376 about?
NCT00974376 is a clinical study titled "Gabapentin Treatment of Cannabis Dependence". This is a clinical study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.
What is the current status of trial NCT00974376?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2009-11-04. Estimated completion is 2016-05-19.
What interventions are being tested in trial NCT00974376?
The interventions under investigation include: Placebo (DRUG), Manual-guided behavioral counseling (BEHAVIORAL), gabapentin 1200mg/day (DRUG).
Who is sponsoring clinical trial NCT00974376?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.